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TObjective: Predominant concerns of patients undergoing valve replacement surgery
are risks of death, stroke, antithrombotic bleeding, and reoperation related to the
replacement prosthesis. The purpose of this study was to compare valve-related
reoperation, morbidity (permanent impairment), and mortality between bioprosthe-
ses and mechanical prostheses for mitral valve replacement.
Methods: Between 1982 and 1998, a total of 959 bioprostheses were implanted in
943 patients, and a total of 961 mechanical prostheses were implanted in 839
patients. Total follow-ups were 5730 years for bioprostheses and 5271 years for
mechanical prostheses. Eight variables were considered as predictors of risk for the
composites of valve-related complications.
Results: The linearized occurrence rates for valve-related reoperation were 3.7
events/100 patient-years for bioprostheses and 0.5 events/100 patient-years for
mechanical prostheses (P  .001), with all age groups differentiated except older
than 70 years. Valve-related morbidity was undifferentiated for bioprostheses and
mechanical prostheses. Valve-related mortalities were 1.7 events/100 patient-years
for bioprostheses and 0.7 events/100 patient-years for mechanical prostheses (P 
.001). Predictors of valve-related reoperation were age and valve type. The only
predictor of valve-related morbidity was age, whereas age and valve type were
predictors for valve-related mortality. Actual freedom from valve-related reopera-
tion favored mechanical prostheses in all age groups except older than 70 years
(91.7%  2.0% for bioprostheses at 15 years and 96.7%  1.5% at 12 years for
mechanical prostheses). Actual freedom from valve-related morbidity was not
different between bioprostheses and mechanical prostheses. Actual freedom from
valve-related mortality favored mechanical prostheses in all groups except older
than 70 years.
Conclusion: Comparative evaluation gives high priority in mitral valve replacement
for mechanical prostheses relative to bioprostheses for freedom from valve-related
reoperation and valve-related mortality but not valve-related morbidity. Freedom
from valve-related reoperation and valve-related mortality favors mechanical pros-
theses for all age groups except older than 70 years. Valve-related morbidity, due to
neurologic or functional impairments, does not differentiate between bioprostheses
and mechanical prostheses.
The long-term performance of bioprostheses and mechanical prostheses inaortic and mitral valve replacement has only been compared in two largerandomized trials.1-5 These trials assessed patient survival and valve-related
complications. There have been no comparisons of long-term performance of
bioprostheses and mechanical prostheses considering composites of valve-related
complications with actuarial and actual methodologies. Jamieson and colleagues6
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formance of porcine bioprostheses. The actual freedoms
from valve-related mortality at 15 years were 85% for aortic
valve replacement and 80% for mitral valve replacement in
patients older than 60 years. The actual freedoms from
valve-related reoperation at 15 years were 88% in patients
aged 61 to 70 years and 96% in those older than 70 years for
aortic valve replacement and 93% in patients older than 70
years for mitral valve replacement. The purpose of this
study was to evaluate composites of valve-related compli-
cations (valve-related mortality, morbidity with permanent
impairment, and reoperation) in populations receiving bio-
prostheses and mechanical prostheses. The patients’ pri-
mary concerns are these long-term risks.
Methods
Between 1982 and 1998, a total of 959 bioprostheses were im-
planted in 943 patients, and a total of 961 mechanical prostheses
were implanted in 839 patients. The patients considered for the
study had undergone no previous cardiac procedures. The overall
mean age differed by prosthesis type: 65.4  11.7 years for
bioprostheses and 59.1  11.8 years for mechanical prostheses (P
 .001) but age category breakdown (40, 41-50, 51-60, 61-70,
and 70 years) did not. Concomitant coronary artery bypass
grafting (CABG) was performed at the initial procedure or valve-
related reoperation for 42.9% of bioprostheses (n 411) or 31.1%
of mechanical prostheses (n 299, P .001). The total follow-up
differed by prosthesis group: 5730.3 years for bioprostheses and
5271.3 years for mechanical prostheses (P  .002). The follow-up
also differed by prosthesis group for the age categories. Complete-
ness of follow-up figures were 99.0% for bioprostheses and 95.4%
for mechanical prostheses.
During the 17-year implantation period, the bioprosthesis types
and numbers of implants were as follows: Carpentier-Edwards
SAV (Edwards Lifesciences, Irvine, Calif; n  857), Carpentier-
Edwards PERIMOUNT (Edwards Lifesciences; n  33), and
Medtronic Mosaic (Medtronic, Inc, Minneapolis, Minn; n  53),
all second and third generation porcine bioprostheses. During this
period the mechanical prostheses were as follows: St Jude Medical
(St Jude Medical Inc, Minneapolis, Minn; n  471) and Carbo-
Medics (Sorin CarboMedics Inc, Austin, Tex, n  313). The
overall valve sizes at the initial procedure were 28.4  2.2 mm for
bioprostheses and 28.2  2.3 mm for mechanical prostheses (P 
.042).
Follow-up Procedure
The patients were followed up periodically throughout the obser-
vation period, with the closing interval in the year 2000 to 2001.
The patients were evaluated by telephone interviews, and health
records and consultations were evaluated when appropriate. The
documentation on reoperative procedures was fully reviewed. The
vital statistics death registry was used to ensure completeness of
mortality data.
Study End Points
The three primary end points were valve-related mortality (inclu-
sive of reoperative mortality), valve-related morbidity, and valve-
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bidity and Mortality After Cardiac Valvular Operations” from the
The Society of Thoracic Surgeons, The American Association for
Thoracic Surgery, and European Association for Cardio-Thoracic
Surgeons.7 Valve-related mortality included death caused by struc-
tural valve deterioration, nonstructural dysfunction, thrombosis,
thromboembolism, hemorrhage, or prosthetic valve endocarditis
and death related to reoperation for a valve-related complication.
Valve-related mortality was inclusive of sudden unexplained, un-
expected deaths. Valve-related reoperation was reoperation for any
valve-related complication. Valve-related morbidity was consid-
ered, for this study, as permanent valve-related impairment as a
result of permanent neurologic or other functional deficit caused
by structural valve deterioration, nonstructural valve dysfunction,
valve thrombosis, thrombotic embolism, bleeding, prosthetic valve
endocarditis, or reoperation.
All valve-related complications were used to calculate the
composites of valve-related mortality, valve-related reoperation,
and valve-related morbidity, with these composites being attrib-
uted to the particular valve type (either bioprosthesis or mechan-
ical prosthesis). When patients had a bioprosthesis explanted and
a mechanical prosthesis implanted or vice versa, they were cen-
sored from the former group and entered into the latter group.
Operative mortality (30-day mortality) was attributed to the ex-
planted prosthesis and classified as valve-related mortality. It is for
this reason the study did not evaluate patient survival, because a
portion of the patients were in both the bioprosthesis and mechan-
ical prosthesis arms of the study.
The variables considered as predictors of risk for the compos-
ites of valve-related complications were prosthesis type, age (con-
tinuous variable), age group (categoric variable), sex, prosthesis
size, and concomitant CABG. All patients undergoing initial car-
diac operations between 1982 and 1998, as well as reoperation in
1999, 2000, or 2001, were included in the analysis.
Statistical Analysis
Differences in baseline characteristics between the two groups
were compared with the t test for continuous variables and 2 for
categoric variables; no adjustment for multiple comparisons was
made. The composites of valve-related complications were calcu-
lated for freedom from the complications composite with the
Kaplan-Meier actuarial methodology and compared by the log-
rank statistic. The actual freedom or cumulative incidence was
determined by the modified Kaplan-Meier methodology of Grunk-
emeier and colleagues.8-11 The composites of complications were
also evaluated as linearized occurrence rates as events/100 patient-
years, with comparisons made with the log likelihood ratio statis-
tic. Linearized occurrence rates are not recommended for evalua-
tion of structural valve deterioration reoperation because of lack of
constant hazard with time but an advancing hazard with time. The
Weibull distribution curve is the appropriate representation of
structural valve deterioration and structural valve deterioration
reoperation. Linearized occurrence rates were used in this study to
depict valve-related reoperation, because valve-related reoperation
was inclusive of all causes of valve-related reoperation: prosthetic
valve endocarditis, nonstructural dysfunction (periprosthetic leak),
and prosthesis thrombosis, as well as structural valve deterioration.
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by univariate analysis and multiple Cox hazard regression analysis.
Results
The linearized occurrence rates for the composites of com-
plications are detailed in Table 1. The linearized rate for
overall valve-related reoperation was 3.7 events/100 pa-
tient-years for bioprostheses and 0.5 events/100 patient-
years for mechanical prostheses (P  .001). The rates were
also different overall for valve-related mortality, at 1.7
events/100 patient-years for bioprostheses and 0.7 events/
100 patient-years for mechanical prostheses (P .001). The
rates were not different (P not significant) for valve-related
morbidity, at 1.5 events/100 patient-years for bioprostheses
and 1.7 events/100 patient-years for mechanical prostheses.
Valve-related reoperation favored mechanical prostheses
for all age groups except older than 70 years, for which the
bioprosthesis rate was 1.2 events/100 patient-years and the
mechanical prosthesis rate was 0.6 events/100 patient-years
(P  .1907). Valve-related mortality only favored mechan-
ical prostheses relative to bioprostheses for the age groups
51 through 60 years and 61 through 70 years. For patients
older than 70 years, the rates were similar, at 2.1 events/100
patient-years for bioprostheses and 1.9 events/100 patient-
years for mechanical prostheses (P  .7194). Valve-related
morbidity was undifferentiated between mechanical pros-
theses and bioprostheses for all age groups.
TABLE 1. Linearized occurrence rates of composites of
valve-related complications by age group
Age
(y)
Reoperation Morbidity Mortality
BP MP
P
value BP MP
P
value BP MP
P
value
40 7.1 0.7 .001 0.7 1.8 .1715 0.7 0.9 .8088
41-50 6.4 0.4 .001 0.7 1.8 .0812 0.9 0.2 .0905
51-60 5.3 0.5 .001 1.3 1.2 .7667 1.0 0.3 .0125
61-70 3.3 0.5 .001 1.6 1.9 .5318 2.2 0.8 .0002
70 1.2 0.6 .1907 2.1 2.8 .8954 2.1 1.9 .7194
Total 3.7 0.5 .001 1.5 1.7 .3140 1.7 0.7 .001
BP, Bioprostheses; MP, mechanical prostheses.
TABLE 2. Predictive risk factors
Reoperation
B HR* P value B
Age 0.020 0.98 (0.97-0.99) .0001 0.0
Sex 0.113 0.89 (0.67-1.20) .4524 0.0
Valve type 1.649 0.19 (0.13-0.29) .001 0.2
Size 0.006 1.01 (0.94-1.07) .8525 0.0
Concomitant CABG 0.275 0.76 (0.54-1.06) .1079 0.0
Baseline assumptions for dichotomous variables: Sex, male; valve type, bio
interval for the hazard ratio is given in parentheses.
The Journal of ThoracicThe predictors of valve-related composites of complica-
tions are presented in Table 2. The predictors of valve-
related reoperation were age and prosthesis type. The mean
age at implantation of patients who underwent a reoperation
(n 240) was 56.0 12.9 years; that for those who did not
(n  1680) was 63.4  11.7 years (P  .001). The hazard
ratio (HR) was 0.98 (95% confidence interval 0.97-0.99,
P  .0001). Reoperation for prosthesis type was performed
in 2.7% of mechanical prosthesis cases (n  26) and 22.2%
of bioprosthesis cases (n 214, P .001). The HR of valve
type for valve-related reoperation was 0.19 (95% confi-
dence interval 0.13-0.29, P  .001, bioprostheses greater
than mechanical prostheses). Among those who underwent
valve-related reoperation, concomitant CABG was per-
formed at initial surgery or valve-related reoperation in
8.6% (n  61/710) and not in 14.8% (n  179/1210, P 
.0001). The HR for concomitant CABG was 1.2 (95%
confidence interval 0.9-1.7, P  .1278).
Age was the only predictor of valve-related morbidity,
with HR 1.02 (95% confidence interval 1.001-1.031, P 
.0302). Age and valve type were the predictors of valve-
related mortality. The mean age of patients with valve-
related mortality (n  133) was 65.3  10.6 years, and that
of patients who did not (n  1787) was 62.2  12.2 years
(P  .002). The HR for age as a continuous variable was
1.041 (95% confidence interval 1.02-1.06, P  .001). The
HR for valve type was 0.61 (95% confidence interval 0.41-
0.93, P  .0202. Valve-related mortality occurred in 8.5%
of female patients (n  88/1034) and 5.1% of male patients
(n  45/886, P  .00421). The HR was 1.4 (95% confi-
dence interval 0.9-2.1, P  .0912, female patients greater
than male patients). Prosthesis type was predictive (biopros-
theses 10.1% [n  97/963], mechanical prostheses 3.8%
[n  36/957]) for valve-related mortality (P  .001, or 1.7
events/100 patient-years for bioprostheses and 0.7 events/
100 patient-years for mechanical prostheses).
The freedom ( SD) from composites of valve-related
complications are detailed for actual and actuarial freedom
to 15 years from valve-related reoperation, valve-related
morbidity, and valve-related mortality in Figures 1 through
6 for age groups 61 through 70 and older than 70 years.
Morbidity Mortality
HR* P value B HR* P value
1.02 (1.00-1.03) .0302 0.041 1.04 (1.02-1.06) .001
1.09 (0.76-1.55) .6533 0.347 1.41 (0.95-2.11) .0912
1.25 (0.90-1.72) .1792 0.486 0.61 (0.41-0.93) .0202
0.98 (0.91-1.06) .6816 0.034 0.97 (0.89-1.05) .4241
1.09 (0.77-1.56) .6233 0.161 0.85 (0.58-1.26) .4198
hesis; concomitant CABG; B, Regression coefficient. *The 95% confidence16
82
22
16
89
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15 years was significantly greater for mechanical prostheses
than for bioprostheses for all age groups other than older
than 70 years (P  .05). The actuarial freedoms for the
group older than 70 years were 82.3%  4.8% for biopros-
theses and 96.7%  1.6% at 11 years for mechanical
prostheses (P not significant). The actual freedom from
valve-related reoperation trended higher for mechanical
prostheses than for bioprostheses for all age groups except
older than 70 years. For the group older than 70 years, the
actual freedoms from valve-related reoperation were 91.7%
 2.0% for bioprostheses at 15 years and 96.7% 1.5% for
mechanical prostheses at 11 years.
The actuarial freedom from valve-related morbidity for
all age groups was undifferentiated between bioprostheses
and mechanical prostheses (P not significant). The actual
freedom from valve-related morbidity was also undifferen-
tiated for all age groups between bioprostheses and mechan-
ical prostheses.
Figure 1. Freedom from valve-related reoperation (actual); 61
through 70 years. Solid line, Bioprostheses; dashed line, mechan-
ical prostheses.
Figure 2. Freedom from valve-related reoperation (actual); older
than 70 years. Solid line, Bioprostheses; dashed line, mechanical
prostheses.
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only different for age 51 through 60 years, at 75.4% 8.3%
for bioprostheses and 87.5%  8.7% for mechanical pros-
theses. There were identifiable trends in actual freedom in
favor of mechanical prostheses relative to bioprostheses for
age groups 41 through 50, 51 through 60, 61 through 70,
and older than 70 years.
The actual and actuarial freedoms from each of the com-
posites for age groups 61 through 70 years and older than 70
years are demonstrated in Figures 1 through 6. The actual
freedoms from valve-related reoperation at 15 years for the age
group 61 through 70 years were 75.2%  2.6% for biopros-
theses and 95.6%  1.8% at 12 years for mechanical prosthe-
ses (Figure 1). The actual freedoms from valve-related reop-
eration for the age group older than 70 years were 91.7% 
2.0% for bioprostheses at 15 years and 97.1%  1.5% at 11
years for mechanical prostheses (Figure 2).
The actual freedoms from valve-related morbidity for the
age group 61-70 years were 89.3%  2.0% for bioprosthe-
ses at 15 years and 86.8%  3.3% at 12 years for mechan-
Figure 3. Freedom from valve-related morbidity (actual); 61
through 70 years. Solid line, Bioprostheses; dashed line, mechan-
ical prostheses.
Figure 4. Freedom from valve-related morbidity (actual); older
than 70 years. Solid line, Bioprostheses; dashed line, mechanical
prostheses.
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years, the freedoms were similar at 15 and 12 years, 88.1% 
2.2% for bioprostheses and 87.2%  3.1% at 11 years for
mechanical prostheses, respectively (Figure 4).
The actual freedoms from valve-related mortality (fa-
vored mechanical prostheses relative to bioprostheses) for
the age group 61 through 70 years were 81.0%  2.8% for
bioprostheses at 15 years and 94.2% 1.6% for mechanical
prostheses at 12 years (Figure 5). The actual freedom at 15
years from valve-related mortality for those older than 70 years
was 84.3%  2.8% for bioprostheses and at 11 years 90.7%
 2.7% for mechanical prostheses.
There were 255 major thromboembolic events, with and
without residual morbidity: 2.3 events/100 patient-years
(n  129) for bioprostheses and 2.4 events/100 patient-
years (n  126) for mechanical prostheses. There were 118
bleeding events with and without residual morbidity: 0.5
events/100 patient-years (n  27) for bioprostheses and 1.1
events/100 patient-years (n  57) for mechanical prosthe-
ses. Of these major events, 178 were associated with resid-
ual morbidity. For thromboembolism (n  94), the rate for
bioprostheses was 1.0 events/100 patient-years (n  59),
and that for mechanical prostheses was 0.7 events/100 pa-
tient-years (n  35). For bleeding (n  84), the rate for
bioprostheses was 0.5 events/100 patient-years (n  27),
and that for mechanical prostheses was 1.1 events/100 pa-
tient-years (n 57). Of these 178 residual morbidity events,
161 were initial events: 88 thromboembolic events (55 for
bioprostheses and 33 for mechanical prostheses) and 73
bleeding events (23 for bioprostheses and 50 for mechanical
prostheses).
There were 214 reoperations in the bioprosthesis group
and 26 in the mechanical prosthesis group. The distribution
by cause of first events was nonstructural dysfunction for 15
bioprostheses and 12 mechanical prostheses, prosthetic
Figure 5. Freedom from valve-related mortality (actual); 61
through 70 years. Solid line, Bioprostheses; dashed line, mechan-
ical prostheses.valve endocarditis for 14 bioprostheses and 2 mechanical
The Journal of Thoracicprostheses, structural valve deterioration for 180 biopros-
theses (n  53 for 51-60 years, n  62 for 61-70 years, n 
11 for 70 years) and 0 mechanical prostheses, and throm-
bosis for 5 bioprostheses and 12 mechanical prostheses.
There were 97 valve-related deaths in the bioprosthesis
group and 36 in the mechanical prosthesis group. The dis-
tribution by cause of first events was bleeding for 9 bio-
prostheses and 14 mechanical prostheses, nonstructural dys-
function for 7 bioprostheses and 2 mechanical prostheses,
prosthetic valve endocarditis for 9 bioprostheses and 4
mechanical prostheses, structural valve deterioration for 34
bioprostheses (n 20 for 61-70 years, n 9 for70 years)
and 0 mechanical prostheses, thromboembolism for 28 bio-
prostheses and 11 mechanical prostheses, thrombosis for 3
bioprostheses and 3 mechanical prostheses, and sudden
unexpected death for 7 bioprostheses and 2 mechanical
prostheses.
Discussion
The long-term performances of bioprostheses and mechan-
ical prostheses have had limited documentation to 15 years.
Most publications on bioprostheses and mechanical pros-
theses have dealt with specific valve-related complications:
thromboembolism and antithromboembolic-related hemor-
rhage for mechanical prostheses and limited durability be-
cause of structural valve deterioration for bioprosthe-
ses.12-14 The past 10 to 15 years have seen reduced use of
mitral valve replacement in favor of mitral valve reconstruc-
tion, especially for degenerative disease.
There have been two large randomized trials comparing
the performance of bioprostheses and mechanical prosthe-
ses.1-5 The United States Veterans Affairs randomized aor-
tic and mitral implantations to the Björk-Shiley spherical
disk mechanical prosthesis or the Hancock porcine biopros-
thesis. The Veterans Affairs study has produced three pub-
Figure 6. Freedom from valve-related mortality (actual); older
than 70 years. Solid line, Bioprostheses; dashed line, mechanical
prostheses.lications, with the final report in 2000 documenting their
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as follows: mechanical valves resulted in a lower mortality
and lower reoperation rate for aortic valve replacement; the
mortality for mitral valve replacement was similar between
prosthetic valve types; primary tissue failure after both
aortic and mitral valve replacement occurred more fre-
quently with a bioprosthetic valve, especially in patients
less than 65 years at implantation; use of the bioprosthetic
valve resulted in a lower bleeding rate; and there were no
differences between the valve types with regard to other
valve-related complications, including thromboembolism
and all complications.
The other randomized trial between bioprostheses and a
mechanical valve, the Edinburgh trial, was reported on in
1991 and 2003.4,5 At 12 years, the study indicated a trend
toward better survival with the mechanical valve. The 20-
year evaluation revealed no difference in survival between
the mechanical prosthesis and bioprosthesis populations.
The study considered combined death and reoperation as
end points and confirmed that patients with mechanical
prostheses had improved survival with the original prosthe-
sis intact. This difference became apparent after 8 to 10
years for mitral valve replacement and after 12 to 14 years
for aortic valve replacement. Major bleeding was more
common with mechanical prostheses, but there was no
difference in major embolism or endocarditis. Other studies
have identified similar survival trends between bioprosthe-
ses and mechanical prostheses.12,13 Demirag and investiga-
tors14 found no difference in survival and reoperation at 10
years in their study evaluating the Biocor porcine biopros-
thesis and St Jude Medical mechanical prosthesis in the
mitral position. In a 20-year comparison study in an elderly
population, bioprostheses did not offer a survival advantage
relative to mechanical valves.15 That study did determine
that anticoagulant-related mortality and morbidity were
higher in patients with mechanical valves. Kassai and col-
leagues16 also evaluated survival in a meta-analysis of ran-
domized clinical trials comparing bioprostheses and me-
chanical prostheses and found no significant influence.
Kawachi and coworkers17 compared the two prosthesis
types in the mitral position and also failed to find any
survival benefit. That study also reported for bioprostheses
in the mitral position only a small benefit in antithrombo-
genesis but a prominent disadvantage in altered durability
necessitating reoperation.
Jamieson and colleagues18,19 have provided considerable
documentation supporting the indications for bioprostheses
and mechanical prostheses. Bioprostheses are recom-
mended for aortic valve replacement in patients older than
65 years and for mitral valve replacement in patients older
than 70 years.6,18,19 Mechanical prostheses are the predom-
inant choice of prosthesis type other than for these age
groups.
1306 The Journal of Thoracic and Cardiovascular Surgery ● JunThis study assessed the composites of valve-related com-
plications—reoperation, morbidity (permanent impairment),
and mortality—by both actuarial and actual methodologies.
Jamieson and colleagues6 previously reported on valve-
related reoperation and valve-related mortality in a porcine
bioprosthesis population. The actual freedom for mitral
valve replacement at 15 years from valve-related mortality
in the age group 61 through 70 years was 79.5% (actuarial
59.5%), and in the age group older than 70 years it was
82.0% (actuarial 26.1%). The actual freedom at 15 years
from valve-related reoperation in the age group 61 through
70 years was 71.0% (actuarial 32.6%), and in the age group
older than 70 years, it was 93.3% (actuarial 83.4%). Those
results are not appreciably different from those in this study.
This study compared the performance of bioprostheses
and mechanical prostheses to 15 years. Actual freedoms
from valve-related reoperation at 15 years for bioprostheses
were less than 50% for patients younger than or equal to 60
years, 75% for those aged 61 through 70 years, and 92% for
those older than 70 years. Mechanical prostheses had a
greater than 94% actual freedom from valve-related reop-
eration in all age groups at 12 to 15 years. There was no
differentiation between bioprostheses and mechanical pros-
theses in freedom from valve-related morbidity (permanent
neurologic or functional impairment) for all age groups. The
freedom from valve-related mortality was extended for all
age groups (88%-99% at 12-15 years) for mechanical pros-
theses, yet relatively stable for all age groups for biopros-
theses (81%-88% at 15 years). There are no comparable
studies in the literature except the previously quoted results
for bioprostheses from our institution.6,18
This study captured all valve-related morbidity and mor-
tality events for both mechanical prostheses and bioprosthe-
ses by censoring patients 31 days after reoperation if the
valve type changed and the patients entered into the new
valve type group. If the valve type did not change at
reoperation, the patients remained in the original groups.
This methodology of patient classification precluded the
determination of patient survival for mechanical prostheses
and bioprostheses, because the patients with successful re-
operations were in both arms of the study. The major
limitation of the study is that the follow-up of the mechan-
ical prostheses did not afford acceptable numbers of patients
at risk between 12 and 15 years.
This comparative evaluation suggests a priority for me-
chanical prostheses relative to bioprostheses with regard to
freedom from valve-related reoperation and valve-related
mortality, but not from freedom from valve-related morbid-
ity because of neurologic or functional impairment. The
recommendation from this center for mitral valve replace-
ment, as documented in previous publications, was to im-
plant bioprostheses in patients older than 70 years and in
selected patients older than 60 years because of life-limiting
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after this comparative study. This study, as do our previous
studies, provides evidence favoring bioprosthesis use in
patients older than 70 years because of the freedom from
reoperation. Our recent publication20 documented excellent
reoperative mortality for structural valve deterioration, with
the risk factors for reoperative mortality predominantly
emergency status and advanced New York Heart Associa-
tion functional class IV. An excellent patient surveillance
system would avoid high risk reoperative surgery and afford
greater freedom from valve-related mortality. The choice of
prosthesis for mitral valve replacement goes beyond the
consideration of composites of complications that cause
reoperation, permanent and functional impairment, or mor-
tality to influential factors inclusive of long-term care with
anticoagulation and the risk of nonmorbid thromboembolic
events and hemorrhagic events. As stated, the design of this
comparative study with crossover of prosthesis type at re-
operation to the alternative type precluded the opportunity
to evaluate patient survival between bioprostheses and me-
chanical prostheses.
We acknowledge and appreciate the word processing of this
manuscript by Kevin Shillitto.
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Discussion
Dr Colleen Sintek (Los Angeles, Calif). Congratulations on your
clear presentation of a comparative analysis of a large series of
mitral valve replacements. You, along with Gary Grunkemeier, Al
Starr, and Craig Miller, have previously demonstrated that the
usual actuarial curves do not provide meaningful percentages of
structural valve deterioration or valve-related morbidity. The ac-
tuarial event-free curve for a nonfatal event estimates the event-
free probability for a population in which death has been elimi-
nated. This overestimates the percentages for valve-related
reoperation and valve-related morbidity, because many patients die
before these events occur. Of more direct clinical relevance, as you
have stated, is the percentage of patients who have valve-related
complications before death.
Your study proposes that valve-related reoperation favors me-
chanical prostheses for all but patients older than 70 years, that
valve-related mortality favors mechanical relative to bioprosthetic
valves for patients 70 years of age and younger, and that valve-
related morbidity is the same for mechanical and bioprosthetic
valves in all age groups. You conclude that patients 70 years of age
and younger requiring mitral valve replacement should receive a
mechanical valve and that for those older than 70 there is no
advantage of bioprostheses relative to mechanical prostheses.
I have several concerns and questions about this report. Your
definition of valve-related morbidity excluded nonpermanent
events. You have already elaborated on that to some extent, but I
and Cardiovascular Surgery ● Volume 129, Number 6 1307
Surgery for Acquired Cardiovascular Disease Jamieson et al
A
CDdid note that in a previous study of your own mitral mechanical
replacements you reported a thromboembolic event rate of 5.5
events/100 patient-years and a hemorrhagic complication rate of
1.5 events/100 patient-years. That is opposed to the 0.57 events/
100 patient-years valve-related morbidity that you report in this
report. Did you exclude peripheral emboli that were successfully
treated surgically or hemorrhage that required transfusion or a
thrombosed valve that was successfully treated with thrombolytic
therapy? Do you believe that such events should be considered
when selecting a prosthesis for a given patient?
Dr Jamieson. You are right, Dr Sintek. In that group of
patients, we did have an incidence of thromboembolism of 5.0
events/100 patient-years, and that included minor events, major
events, RIND (reversible ischemic neurologic deficits), and throm-
bosis. For this particular study, we went on the understanding that
the patients were really concerned whether they would die from
the valve, would have a reoperation, or would have permanent
impairment. We did alter that definition, and we do describe what
we did here. There is no question that the nonmorbid events are
still important to the patient, but we did try and differentiate here
as to whether or not the patient had a permanent neurologic
impairment in particular.
Dr Sintek. I am concerned about the shorter follow-up for your
mechanical valve population. In fact, I am not sure that there are
enough patients older than 70 years at risk—even at 10 years, there
were only 7 patients—to come to a valid conclusion in comparison
with the bioprosthetic group.
Dr Jamieson. Yes, I do agree with you. We commenced this
follow-up about 3 years ago, and we are concerned about the lesser
number of patients at risk at the advanced years in the mechanical
prosthesis population. It is conceivable even today that if we went
back and followed those mechanical valves again, we would add
greater numbers at the extended years. I think that is part of this
whole work in process. That is important, and I take your criticism
as valid.
Dr Sintek. You found no difference in the need for reoperation
in patients undergoing concomitant CABG with mitral valve re-
placement, although previous CABG was a predictor for valve-
related reoperation. Could you elaborate on this?
Dr Jamieson. I’ll answer the second question first. Those
patients who had previous CABG obviously have an anticipated
reduced life expectancy because of this comorbid disease. Conse-
quently, because of reduced life expectancy, they have a reduced
potential for reoperation. The other important part of this though,
is that among those patients for whom we did concomitant CABG
at the time of reoperation, that was not a factor. This is probably
related to a study we presented at the American Heart Association
meeting in November, in which we found that in the last 7 years
1308 The Journal of Thoracic and Cardiovascular Surgery ● Junwe reduced our valve-related mitral mortality to 3.4%, among
those with concomitant coronary bypass, to 2.8%, so these are
influential factors in here that are coming through. Concomitant
coronary bypass is not a predictor because of our last 8-year
experience.
Dr Sintek. This is a comparative study, not randomized. Did
cardiac rhythm play a role in selecting a prosthesis for a given
patient? And could you share with us your anticoagulation proto-
col for both bioprosthetic and mechanical valves in the mitral
position?
Dr Jamieson. We looked at rhythm as a factor here, and it did
not come out in univariate analysis as being a predictor. As far as
anticoagulation goes, the majority (and I just say the majority
because there are 15 surgeons in this group) do use anticoagulation
early and for at least 6 weeks in those patients who are in sinus
rhythm and do not have other extenuating factors as risk factors for
venous stasis in the atrium, and those patients would be anticoag-
ulated and then switched to aspirin if they had a bioprosthesis and
obviously continued on if the prosthesis was mechanical. The
patients with mechanical prostheses were always anticoagulated
early. In recent years, we have also been using low-dose heparin,
and I might share with you some information from the AVERT
(Artificial Valve Endocarditis Reduction Trial) trial that patients
who were on heparin early postoperatively also had a reduced
incidence of late thromboembolic events. This is a factor not yet
fully explored.
Dr Sintek. Last, applying the lessons learned from your study,
what type valve would you implant in a 69-year-old man in sinus
rhythm requiring mitral valve replacement and CABG?
Dr Jamieson. Well, there are certainly factors here that are not
readily apparent. You have to look at the bioprosthesis that you are
using. A large group of these patients were implanted with Car-
pentier-Edwards supra-annular valves in the mitral position, and
we found a few years ago and actually presented at the Western
Thoracic Surgical Association meeting that the supra-annular por-
cine valve did not fare as well as the Carpentier-Edwards PERI-
MOUNT pericardial valve. We have now a 6-year experience with
the Medtronic Mosaic. The other factor to be considered, coming
out of the experience in Sweden, and this perhaps is going to be
brought out next weekend at the Society for Heart Valve Disease,
is that those porcine valves that are formulated as a tricomposite
configuration with three separate leaflets appear to have extended
durability in the mitral position. So looking at those things and
what is coming forward in the future and what will be available
even in North America on a trial basis within a couple of months,
I might certainly consider an advanced generation bioprosthesis
for the patient in sinus rhythm undergoing concomitant CABG.
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